Novo Nordisk faces consolidated federal litigation in Pennsylvania over allegations that its popular diabetes and weight-loss medications, Ozempic and Wegovy, cause severe gastrointestinal complications without adequate patient warnings. The multidistrict litigation (MDL) combines hundreds of individual cases alleging the pharmaceutical manufacturer failed to properly warn patients and healthcare providers about gastroparesis risks.

Gastroparesis: Hidden Risk of “Stomach Paralysis”

The core legal allegation centers on gastroparesis, commonly known as “stomach paralysis,” a debilitating condition that can permanently impair digestive function and require lifelong medical management. While current drug labeling mentions mild gastrointestinal side effects like nausea and vomiting, plaintiffs argue these warnings fail to convey the potentially permanent and severe nature of gastroparesis.

Gastroparesis involves delayed stomach emptying that can cause persistent nausea, vomiting, abdominal pain, and nutritional deficiencies. The condition significantly impacts quality of life and may require ongoing medical intervention including dietary modifications and specialized treatments.

Product Liability and Failure to Warn Claims

The consolidated lawsuits proceed under product liability theory of “failure to warn,” which holds manufacturers responsible for adequately informing patients and doctors about known risks associated with their medications. Plaintiffs contend that Novo Nordisk possessed knowledge of gastroparesis risks but failed to provide sufficient warnings to enable informed medical decision-making.

These legal claims do not seek to ban Ozempic or Wegovy but rather demand pharmaceutical accountability for proper risk disclosure and informed consent procedures.

Multidistrict Litigation Process

The MDL consolidation streamlines pretrial proceedings for hundreds of individual cases by centralizing discovery, expert testimony, and motion practice before a single federal judge. This process increases efficiency while preserving individual plaintiffs’ rights to trial if cases do not settle during coordinated proceedings.

Pharmaceutical Liability and Patient Safety

This litigation highlights ongoing tensions between beneficial medication effects and undisclosed adverse reactions. While these medications provide significant benefits for diabetes management and weight loss, patients deserve complete information about potential serious side effects to make informed treatment decisions with their healthcare providers.